With the prevalence of ischemic heart disease, early diagnosis and management of myocardial infarction is important,andnecessitatestheneedforcardiacbiomarkers.
Introduction
Acute coronary syndromes (ACS) represent a range of ischemicheartdiseasefromunstableanginatomyocardial infarction (MI), and may include large areas of cardiac necrosis (1) .Thesymptomaticmanifestationsofanacute MI(AMI)maybevaried,andECGisalsonon-diagnostic in about 50% of cases, which poses a risk for potential misdiagnosis. Hence, biochemical markers and cardiac enzymes are considered not only important, butessential, forthediagnosisofmyocardialinfarction (2) . Initially,transaminasesandcreatinekinase(CK)wereused as diagnostic markers, and gradually, improved markers like CK myocardial band (CK-MB) evolved and have been used to diagnose AMI and assess cardiac damage. Their non-specificity has been an issue which has led to the introduction of more specific and sensitive cardiac biomarkers, (for e.g. troponins). Troponins are more efficaciousthanearliermarkersbecausetheyaidnotonly in diagnosis, but also in risk assessment and therapeutic decision-making.However,thesearchforanidealcardiac markercontinues,althoughtroponinsseemtohavemany qualitiesofanidealmarker(3).
Characteristics of an Ideal Cardiac Marker
An ideal cardiac marker would guide physicians in evaluation,butsuchamarkerdoesyetexist.Researchers havehypothesizedseveralcharacteristicsofsuchanideal marker (4). High specificity is important for a cardiac biomarker to be ideal, and higher concentrations of the marker should be seen in the myocardium, with lower concentrations seen in non-cardiac tissue (2) . Tissue distributionofthemarkerisimportant,bothinphysiological aswellaspathologicalconditions.Thespeedwithwhichthe markerisreleasedfrominjuredmyocardiumisimportant. Appearance in the bloodstream soon after injury may facilitateearlydiagnosis.Fore.g.,troponinsshowaninitial release with peak concentration at 12-24 hours of injury and a second peak 2-4 days after injury. The continuous breakdownleadstoprolongedandsustainedelevationsof troponinswhichaidsindiagnosis (3) . Assays also benefit if the marker has a short turn-around time,asitaddswithbothsensitivityandspecificitywithin aclinicalframe.Prolongedelevation,asseenintroponins, maybebeneficialisdiagnosingpatientswhopresentlate; however, they have the disadvantage of not being able to detect reinfarction. In such situations, markers with a shortertimecourse,suchasCK-MBaremoreusefuland have been recommended in both early as well as recent guidelines (5, 6) . Assessment of infarct size is possible by serial marker concentration vs. time; however, this has been found to beinaccurateinsomesituations (7) .
ThoughCK-MBwas earlier used as a standard marker, troponins have more characteristics of an ideal marker and are now preferred, except in situations where CK-MB offers an advantage, as discussed. The present review will focus on the key, clinicallyuseful, cardiac markers. Discussion about other uncommonlyusedmarkerswouldbebeyondthescopeof thisreview.Hence,ouremphasiswillbeontheusefulness oftroponinsandCK-MBindifferentclinicalsituations.Our goal is that such a concise review would help physicians updatetheirknowledgeandenabletheminearlydiagnosis/ management of patients with AMI which would allow minimizationofassociatedmorbidity/mortality.
Troponins
Two types of troponins, troponin T (cTnT) and troponin I(cTnI)areidealmarkerswhicharehighlysensitiveand specific for myocardial injury and have shown better efficacythanearliermarkers(Table1) (8) . Elevatedserum levelsoftroponinaredetectablewithin4to8hoursafter the onset of chest pain, reaching peak concentration in approximately12-24hours(3),andremainingelevatedfor 3-10daysfollowingAMI,givingthemawidediagnostic windowwhichextendsbeyondthewindowofothercardiac markersgivingthemanadvantage (Fig 1)(9) .Troponins have been useful in a wide variety of clinical situations. CK-MB is also emphasized, wherever relevant; however, anexclusiveattempttogiveanoverviewofdisadvantages/ advantagesofCK-MBwillbemadelater. (10) . The low background concentration of troponins with the fact that they provide evidence of a myocardial infarct havingdevelopedupto10daysearlier(incontrasttoother markers), gives them an advantage. They have replaced CK-MBasthestandardmarkerinACS(11).
Role, Usefulness and Clinical Advantages of Troponins
Chest pain and diagnosis of angina/ MI Rapidandaccuratediagnosisofchestpainisessentialas thrombolysisorimmediatetherapeuticcoronaryangioplasty reducesmorbidityandmortality,andbothearlierandrecent ACC/AHAguidelinesemphasizethisimportance (12, 13) . Becauseofatypicalpresentationandnon-diagnosticECGs, diagnosisbycardiacmarkershasbecomevital.Once,CKMBwasconsideredthe"goldstandard"serummarkerfor MI. However, it lacks specificity for cardiac tissue and a raisedvalueisnotseentill6-8hoursafteronsetofanAMI (14) . CK-MBisstillusedintheabsenceoftroponins,butbecause ofitslimitations,researchhaspavedthewayfortroponins to replace CK-MB as the 'gold standard' diagnostic marker. Myoglobin is also used as an early marker but lacks specificity and requires associated cardiac troponin measurementstoconfirmmyocardialinjuryandeliminate myoglobinfalse-positives (15) . The high sensitivity of cardiac troponin assays enables it to be useful in patients with unstable angina, where the degreeofcardiacinjuryisminorandconsiderablylessthan in AMI. Outcome studies have shown that patients with unstableanginaandabnormalcardiactroponinlevelshave a 5-fold increased risk forAMI and cardiac death within 4to6weeksthandopatientswithnormaltroponinlevels (16) . Thus, measurement of troponin in blood has a dual role:whileabnormallyhighconcentrationsareindicative ofAMI,mildlyabnormalconcentrationssuggestapatient is at increased short-term risk for a future cardiac event. (20) . In perioperative myocardial injury (cardiac and noncardiac surgery) Diagnosis of perioperative MI is problematic because of themarkersreleasedfromthedamagedskeletalmuscleas wellasfromthemyocardiumduringcardiacsurgery (12) . Consequently,non-specificmarkersarefrequentlyelevated and are not of much use. Perioperative and immediate postoperative AMI in non-cardiac surgeries also pose a challenge as non-specific cardiac markers are frequently elevated due to skeletal muscle trauma during surgery. Themeasurementoftroponinsissensitiveandspecificfor the detection of perioperative MI following orthopedic, abdominal, and vascular surgery, as well as in coronary artery bypass surgery (CABG). It remains an important predictorofin-hospitalmortalityaftercardiacsurgery (21) . Troponinshavebeenreportedtobeanindependentpredictor of early postoperative cardiovascular complications followingnon-cardiacsurgery,apartfrombeingidentified as an early predictor of short-term mortality in vascular surgerypatientsaswellasapredictorofMIanddeathafter CABG (17) .
ESC/ACC recommend the use of troponins for the detection of MI after cardiac surgery. The close correlation of troponin levels to development of new wall motion abnormalities having both short-and longtermprognosticvalue.Thisisamajorstepforwardinthe diagnosis of perioperativeAMI in both cardiac and noncardiacsurgery (22) .
Role in percutaneous coronary artery intervention (PCI)
Myocardial damage after PCI (due to procedural complicationssuchasincidentalsidebranchocclusionand thrombus formation with embolization) is common and showsassociatedelevatedtroponinlevels (23 (27) .
Detecting myocardial reinfarction
Reinfarction is difficult to detect with any biomarker, and the same applies to troponins. An increased pattern of cTnI has been seen in patients with AMI who had a reinfarction, and re-elevations in cTnI was demonstrated tobesubstantial (28) .Earlierfindingshavealsosuggested that changes in troponin levels are adequate to diagnose reinfarction. However, CK-MB appears more suited for detectingreinfarction.
Detection of reperfusion
Coronary recanalization occurs after AMI, and serial measurementsoftroponinlevelscanassesscoronaryartery patencyandaidinbiochemicalassessmentofreperfusion therapy (29) . This is especially valuable at times when mechanicalintervention,suchasrescue angioplasty,could beofbenefittothepatient,astroponinlevelsgiveagood index ofreperfusion. Cardiactroponinshavealsobeenshown tobeadvantageous fortheearly,noninvasivedetermination of coronary reperfusion following thrombolytic therapy (30) . Based on documented angiography, a significantly 
Limitation of Elevated Troponins as Cardiac Marker: False Positives
TroponinelevationsmaynotbeassociatedwithACS.Such falsepositivescanbeseeninarangeofclinicalsituations (33) . About41%patientswithelevationsintroponinwithout ACS were seen to have other non-thrombotic conditions, including non-ischemic cardiac disorders, pulmonary embolism, sepsis, stroke, trauma, internal bleeding, and renal failure. Other related conditions where troponins maybeelevatedwithoutACSarewithhypovolemia,atrial fibrillation, congestive heart failure, myocarditis, and myocardialcontusions (34) .Althoughtroponinsarespecific formyocardialinjury,theyarenon-specificforetiological cause (33) . However, elevation of troponins in non-ACS patientsareseentobeassociatedwithpooroutcomes;and should be alarming since it often indicates an underlying worseningclinicaletiology,althoughnotACS.
Creatinine Kinase Myocardial Band
Though troponins offer several advantages over CK-MB, certainsituationswarrantCK-MBasthepreferredmarker. To have an insight, it is important to understand salient featuresofCK-MBanditsmechanismofaction.
Role and salient features CK-MBwasonceconsideredthegoldstandardfordiagnosis ofMI.However,sinceitlacksspecificityandlevelsmay not be elevated even 6-8 hours after onset of symptoms, CK-MBisoformshavebeenused.CK-MBisoformshave reducedthistimeto2hours.TheCK-MBisoformistwice as sensitive as conventional CK-MB. Its sensitivity in detecting AMI at 6 hours reportedly increased to 95.7% comparedwith48%forconventionalCK-MB (35 Around5%ofallCKactivityisfromCK-MBinskeletal muscles,whichareknowntoriseundercertainphysiologic conditions(heavyexercise/marathonrunners),diseasestates (genetic/acquired myopathies), and even neoplasms (37) . ThoughthecirculatingplasmacatalyticactivityofCK-MB limitsitsusefulnessforassessingnecrosisofmyocardium, a way to improve the cardiospecificity of CK-MB was determinedbyexpressingitasthequotientoftotalcatalytic activityofcirculatingCK,andthenacertaincutoffplasma level in skeletal muscle could be considered as a sign of its being released from myocardium. Determining mass concentration of CK-MB by immunoassays, rather than catalyticactivity,hasalsohelpedinaddingtoitsincreased sensitivityandaccuracy (17) . CK-MBhasbeenconsideredabenchmarkmarker.Ithasbeen usedasacomparativevalueforothermarkers (36) .Hence, though diagnostic of specific myocardial injury, skeletal muscle shows higher activity. However, the characteristic riseandfallofCK-MBmeasuredseriallyisstillconsidered pathognomonicindiagnosisofMI (36) .Thefirstelevation in CK-MB may be 4-6 hrs after onset of symptoms; however, for increased sensitivity and specificity, serial measurementsoveraperiodof8-12hareadvised.Gibler et al (38) .measuredsamplesatpresentationandthenat3, 6,and 9hoursinlow-riskpatientswithMI(non-diagnostic fromECG),anddemonstratedasensitivityandspecificity of100%and98.3% forMIdiagnosis,respectively,inthese chestpainpatients (38) .
Advantages within limitations of CK-MB in detecting re-infarction
As discussed, CK-MB concentration shows increased plasma levels beginning 4-6 hours after symptoms of AMI and remain elevated till 24-36 hours after onset of symptoms. Because of this sudden rise and subsequent earlyfall,CK-MBisoftenadvantageousandusedtodetect reinfarction.However,sinceCK-MBisnotanearlymarker of infarcted myocardium, levels have been shown to be normalin35-50%ofAMIpatients,anobviouslimitation (17) .Importantly,CK-MBisusedtoassessre-infarction or infarctextension.However,inspiteofgoodperformance, itsrisemaytake8-12 hoursafteronsetofsymptomsand itsnon-specificitymakeforbothersomeissues (36) .Despite the limitations, CK-MB has a crucial role in diagnosis, especiallyinabsenceoftroponins,andinreinfarctioncases.
Measuring CK-MB 2/CK-MB1 ratio
After tissue necrosis, CK-MB2 is quickly released to plasmaandgetsrapidlyconvertedtoCK-MB1.Normally, the tissue isoform variant (CK-MB2) is in equilibrium withtheplasmaisoforms(CK-MB1),withtheratiobeing closeto1.0.DuringAMI,largeamountsofCK-MB2are releasedwhicharenotcompletelyconvertedtoCK-MB1 inplasma,leadingtoahigherratioofCK-MB2/CK-MB1 (≥1.5).Presenceofanincreasedratiohashighdiagnostic sensitivityfornecrosisofmyocardialtissues,especially0-6 hoursafteronset(39).
Measuring CK-MB isoforms has shown a significant (92%) diagnosticrateofMIwithinthefirst6hours after chestpain,thoughmaindiagnosticvalueisduetothehigh negativepredictivevalue.CK-MBisoformswereshownto be quite sensitive (91%) in early diagnosis (<6 hours) of AMI in one study of emergency patients with chest pain (40) .
However,becauseoflesscardiospecificityandlevels notbeingeasilyobtained,itintroducessubjectivityintothe interpretation of results. These disadvantages have led to anincreaseduseoftroponinsthanCK-MBoritsisoforms indiagnosingAMI.Andasstatedearlier,troponinshave nowreplacedCK-MBasthe'goldstandard'fordiagnosis ofmyocardialinjury (4) . Conclusion Troponinshaveusheredinaneweraofhighlyspecificand sensitive cardiac markers used in various cardiovascular clinical situations. Having replaced CK-MB as the gold standardfordiagnosisofMI,theyhavealsoprovedtobe agoodprognosticindicatorbyriskstratificationaswellas atherapeuticguideusedinhigh-riskpatientswithunstable angina. Troponins are shown to help in the diagnosis of post-PCIinfarctionandinperioperativecardiacandnoncardiac surgeries. They are also proving to be beneficial in estimation of infarct size, detection of reinfarction, and detection/evaluation of reperfusion and coronary recanalization.Theirusefulroleinassessingcardiovascular morbidityinchronicrenalinsufficiencyandpatientswith ESRD is proving to be an additional boon. With many qualities of an ideal marker, troponins are favorably set to significantly aid in the management of the rising cardiovascular morbidity and mortality. However, certain clinicalsituationsstillwarrantCK-MBastheidealchoice of cardiac biomarker, especially in cases of detecting reinfarctions.
